Stockscreener 앱 받기
11.15
0.90%
0.10
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading - Defense World
Theravance Biopharma (TBPH) Receives New Analyst Coverage with a Buy Rating | TBPH Stock News - GuruFocus
(TBPH) Proactive Strategies - news.stocktradersdaily.com
Theravance Biopharma (TBPH) Gains Buy Rating with Promising Drug Prospects | TBPH Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance and Mylan settle patent dispute with Eugia Pharma - MSN
theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa
Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha
Theravance BiopharmaTheravance And Mylan Enter Settlement Agreement With EugiaSEC Filing - MarketScreener
Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks
theravance biopharma settles patent litigation with eugia pharma - Investing.com
Theravance Biopharma Sells Remaining Trelegy Royalties to GSK for $225 Million - Global Legal Chronicle
(TBPH) Investment Analysis - news.stocktradersdaily.com
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - sharewise
ProShare Advisors LLC Takes Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC - Defense World
Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - marketscreener.com
Theravance Biopharma Sells Trelegy Royalty Interest to GSK - TipRanks
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in T - GuruFocus
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - Eagle-Tribune
Ameriprise Financial Inc. Cuts Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Nuveen Asset Management LLC Buys 48,635 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Deutsche Bank AG Purchases 15,608 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Jane Street Group LLC Has $493,000 Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Bank of America Corp DE Increases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - Barchart.com
(TBPH) On The My Stocks Page - news.stocktradersdaily.com
Northern Trust Corp Has $3.67 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance
Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine - Investing.com Canada
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by StockNews.com - Defense World
When (TBPH) Moves Investors should Listen - news.stocktradersdaily.com
Theravance Biopharma to Participate in an Upcoming Investor Conf - GuruFocus
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune
Price T Rowe Associates Inc. MD Buys 9,315 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Dimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma Announces Ampreloxetine Presentations at th - GuruFocus
Theravance Biopharma, Inc. Announces Ampreloxetine Presentations At the International MSA Congress - marketscreener.com
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - TradingView
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - Stock Titan
Theravance Biopharma: Promising Future with Strong Product Pipeline and Market Expansion - TipRanks
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights - GuruFocus
Tower Research Capital LLC TRC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - The AM Reporter
Wells Fargo & Company MN Has $204,000 Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Progress Amid Challenges - GuruFocus
Theravance Biopharma Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecast - Investing.com
Theravance Biopharma Q1 2025 slides: revenue growth amid widening losses - Investing.com Canada
Theravance Biopharma earnings missed by $0.05, revenue topped estimates - Investing.com Canada
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecast By Investing.com - Investing.com India
0.68%
0.50%
자본화:
|
볼륨(24시간):